eShowcase: CogState DataPoint
Web-based system puts sponsors running brain function clinical trials in the know
Web-based system puts sponsors running brain function clinical trials in the know
CogState Ltd. (Melbourne, Australia) has released the first real-time cognitive data monitoring system, called DataPoint, which allows pharmaceutical companies to access, monitor, and review data from global, multicenter trials at a central and secure Web-based location. The tool is targeted toward trials where cognitive function is the primary endpoint and represents a significant technological departure from paper and pencil cognitive brain function measurements.
One of the main benefits, says CogState, is that DataPoint enables clinical researchers to respond much more quickly to data coming out of clinical trials. For example, DataPoint delivers cleaned datasets and cognitive reports to pharmaceutical clients within hours of study completion, compared to the usual weeks. DataPoint also functions as the main point of contact between sponsors and CogState, and all study-specific software and manuals required to upload data and run a trial are accessible from one central source.
CogState Ltd., +61-3-9664-1300, www.cogstate.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.
